Uveitis Market By 2024

Global Market Study on Uveitis Treatment:
Europe Market Projected to Represent Market
Attractiveness Index of 1.3

P e r s i s t e n c e M a r k e t R e s e a r c h
Report Media Releases
Uveitis Treatment Market Revenues Poised to Reach US$
847.8 Mn by 2024-End
The US$ 497 Mn uveitis treatment market is likely to expand at a stable CAGR of 6.5% over the
next eight years. In 2017, the market is expected to witness nearly 6.7% Y-o-Y growth over
2016. During 2016-2024, Persistence Market Research predicts a positive growth outlook for the
global uveitis treatment market, influenced by several growth drivers, restraints, trends, and
opportunities.
In its recently published report titled “Uveitis Treatment Market: Industry Analysis and
Forecast, 2016–2024,” the company provides in-depth analysis of the market growth prospects
for the eight-year assessment period, backing it up with historic and current market data.
Persistence Market Research identified a few important drivers and trends that will
continue to present attractive growth opportunities during 2016-2024.
While surge in autoimmune disorders is identified to primarily generate the demand for uveitis,
the market has been witnessing strong emergence of immunosuppressive therapies to treat
uveitis since the past few years, which is expected to create a new set of opportunities for
leading players in near future.
A Sample of this Report is Available Upon Request @
http://www.persistencemarketresearch.com/samples/3596
“Some of the leading companies in the uveitis treatment marketplace have been investing in
new, improved product launches since the past decade. While a significant number of uveitis
drugs are already in the pipeline, increasing in-licensing approvals for new market entrants will
boost the scope of treatment against uveitis, ultimately creating new lucrative opportunities,”
states Persistence Market Research.
Increasing demand for generic drugs also prompt at an important trend in the global
uveitis treatment market that will reportedly generate a range of opportunities for
established as well as new pharma players.
In addition to growing R&D activities in the field of eye disorders, rising optometric clinical
practice will also provide an impetus to market growth.
With surging uveitis prevalence, a host of biological drug development projects is
anticipated to push the potential of the uveitis treatment market.
Moreover, growing prevalence of TB associated with intermediate uveitis will continue to
push the opportunities in intermediate uveitis segment.
Another proliferating trend in uveitis treatment market includes increasing demand for
local steroid implants, especially for non-infectious posterior uveitis.
As corticosteroid mono-therapy is no more considered the first line treatment for uveitis,
the market has been witnessing introduction of various modified corticosteroid
medication and drug delivery methods since the recent past.
Major players in the segment are working to add novel drugs to their product portfolio.
R&D in topical agents segment will also benefit the market growth in near future.
Segmentation by treatment type:
Corticosteroids
North America Wound Debridement Products Market by 2024

P e r s i s t e n c e M a r k e t R e s e a r c h
Immunosuppressants
Monoclonal antibodies
Cycloplegic agents
Antibodies
Antivirals
Antifungals
Analgesics
Corticosteroids will remain the largest segment, followed by antibiotics and monoclonal
antibodies. While corticosteroids segment is foreseen to account for a dominant market share of
over 21% in 2024, antibiotics segment is expected to witness the fastest growth at a CAGR of
8% – reaching beyond US$ 146 Mn over 2016-2024. Monoclonal antibodies segment will also
exhibit healthy growth at a CAGR of 7%, reaching revenues worth US$ 142.7 Mn by the end of
2024.
Segmentation by disease type:
Anterior uveitis
Posterior uveitis
Intermediate uveitis
Panuveitis
Anterior uveitis segment will continue to dominate. Through 2024, this segment will capture
around 60% value share, representing a value of over US$ 500 Mn. Posterior uveitis is also
estimated for a considerable market value share of over 23% in 2024. Attributed to increased
prevalence of TB in intermediate uveitis, the intermediate uveitis will possibly be the second
fastest growing segment over the forecast period.
Segmentation by cause:
Infectious
Non-infectious
On the basis of cause, infectious uveitis will remain the larger segment with over 87% share by
2024 end but non-infectious uveitis is predicted to witness a higher CAGR of 7.4% during the
eight-year period.
Segmentation by distribution channel:
Hospital pharmacies
Retail pharmacies
Online pharmacies
Drug stores
By distribution channel, hospital pharmacies segment will account for over 46% revenue share in
2024, whereas retail pharmacies segment is likely to capture around 30% share. Online
pharmacies and drug stores segments will also witness healthy growth at over 6% CAGR during
the aforementioned period.
Segmentation by region:
The report provides regional analysis that examines the global market classifying it into five key
regions.
North America
Latin America
Europe
North America Wound Debridement Products Market by 2024

P e r s i s t e n c e M a r k e t R e s e a r c h
Asia Pacific (APAC)
Middle East and Africa (MEA)
North America, the largest and fastest growing regional market for uveitis treatment globally, will
retain its dominant position over the assessed period. With over 34% market value share in
2024, this regional will possibly account for around US$ 290 Mn. Europe will remain the second
key market with nearly 27% share by the end of forecast period, followed by Asia Pacific.
View Report Table of Contents, Figures, and Tables
The report profiles key market players and highlights their recent activities supporting
market growth.
Allergan, Inc., Novartis AG (ALCON), Valeant Pharmaceuticals International, Inc., AbbVie Inc.,
Eyegate Pharmaceuticals, Inc., Alimera Sciences Inc., and pSivida Corp. are some of the key
players in the global uveitis treatment market.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/marketresearch/uveitis-market/toc
Among these, Allergan, Valeant, and Novartis constitute the most prominent companies.
Eyegate is also actively involved through strategic acquisitions.
Allergan, in 2016, acquired a gene therapy company RetroSense Therapeutics to
enhance the company’s eye care product pipeline. Later, the same year, Allergan
launched an influential uveitis drug Taytulla.
Novartis recently acquired Encore Vision, Inc. in 2016, to strengthen its ophthalmology
pipeline.
Recently in 2015, Eyegate signed a licensing agreement with Valeant for an effective
combination product against uveitis. More recently in 2016, the company announced the
acquisition of Jade Therapeutics, Inc. and stepped into treatment for poorly-served
ophthalmic indications.
Browse Complete Report @ http://www.persistencemarketresearch.com/marketresearch/uveitis-market.asp
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a
unique collaboration of data analytics and market research methodology to help businesses
achieve optimal performance.
North America Wound Debridement Products Market by 2024

P e r s i s t e n c e M a r k e t R e s e a r c h
To support companies in overcoming complex business challenges, we follow a multi-disciplinary
approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying
real-time data collection, big data, and customer experience analytics, we deliver business
intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized solutions to
cater to client-specific needs, and consulting services to offer more value addition. Our nextgeneration
research approach for exploring emerging technologies has allowed us to solve the
most complex problems of clients. We do not follow a reactive approach, but a pro-active one.
Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and
provide the latest insights into these technologies when they are being commercialized. Our
ground-breaking approach allows us to deliver market solutions before the technologies reach
the market.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing
startups. PMR’s collaborative environment is committed to building industry-specific solutions by
transforming data from multiple streams into a strategic asset.
Contact Us:
Persistence Market Research
90 Sate Street, Suite 700 Albany, NY 12207
Tel: +1-518-618-1030
Email: sales@persistencemarketresearch.com
Website: http://www.persistencemarketresearch.com/
media@persistencemarketresearch.com
Stay updated with our official Blog: http://pmrblog.com
North America Wound Debridement Products Market by 2024